• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

The National Institute on Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical Trials Network (CTN) in 1999 to bring researchers and treatment providers together to develop a clinically relevant research agenda. Initial CTN efforts addressed the use of buprenorphine, a mu-opioid partial agonist, as treatment for opioid dependence. Strong evidence of buprenorphine's therapeutic efficacy was demonstrated in clinical trials involving several thousand opioid-dependent participants, and in 2002, the Food and Drug Administration approved buprenorphine for the treatment of opioid dependence. With the advent of a sublingual tablet containing both buprenorphine and naloxone to mitigate abuse and diversion (Suboxone), buprenorphine appeared poised to be the first-line treatment for opioid addiction. Notwithstanding its many attributes, certain implementation barriers remained to be addressed in CTN studies, and these efforts have brought a body of knowledge on buprenorphine to frontline clinicians. The purpose of this article is to review CTN-based buprenorphine research and related efforts to overcome challenges to the implementation of buprenorphine therapy in mainstream practice. Furthermore, this article explores current issues and future challenges that may require additional CTN efforts.

Pubmed ID: 20307796

Authors

  • Ling W
  • Jacobs P
  • Hillhouse M
  • Hasson A
  • Thomas C
  • Freese T
  • Sparenborg S
  • McCarty D
  • Weiss R
  • Saxon A
  • Cohen A
  • Straus M
  • Brigham G
  • Liu D
  • McLaughlin P
  • Tai B

Journal

Journal of substance abuse treatment

Publication Data

June 23, 2010

Associated Grants

  • Agency: NIDA NIH HHS, Id: K24 DA022288
  • Agency: NIDA NIH HHS, Id: K24DA022288
  • Agency: NIDA NIH HHS, Id: U10 DA 13036
  • Agency: NIDA NIH HHS, Id: U10 DA 13045
  • Agency: NIDA NIH HHS, Id: U10 DA013045
  • Agency: NIDA NIH HHS, Id: U10 DA013045-09
  • Agency: NIDA NIH HHS, Id: U10 DA013045-10
  • Agency: NIDA NIH HHS, Id: U10 DA13732
  • Agency: NIDA NIH HHS, Id: U10 DA15831

Mesh Terms

  • Administration, Sublingual
  • Buprenorphine
  • Clinical Trials as Topic
  • Community Health Services
  • Drug Combinations
  • Humans
  • Naloxone
  • Narcotic Antagonists
  • Narcotics
  • National Institute on Drug Abuse (U.S.)
  • Opioid-Related Disorders
  • Receptors, Opioid, mu
  • United States